ZS Pharma & AstraZeneca v. Sandoz: LOKELMA Patent Dispute Ends in Consent Judgment
ZS Pharma and AstraZeneca pursued patent protection for LOKELMA (sodium zirconium cyclosilicate), their blockbuster hyperkalemia treatment, against Sandoz’s ANDA filing. The Delaware District Court action resolved in a consent judgment and confidential settlement after 334 days — before any merits determination.
LOKELMA ANDA battle ends quietly — but with an injunction on record
ZS Pharma, Inc. and AstraZeneca Pharmaceuticals LP filed suit on 20 October 2023 in the District of Delaware against Sandoz, Inc., asserting US11738044B2 — a patent covering sodium zirconium cyclosilicate formulations marketed as LOKELMA — in response to Sandoz’s abbreviated new drug application (ANDA) seeking to launch a generic equivalent. The case was assigned to Judge Jennifer L. Hall and proceeded as a standard Hatch-Waxman ANDA infringement action.
The parties reached a negotiated resolution and on 18 September 2024 — 334 days after filing — the court entered a consent judgment. Critically, the parties also stipulated to an injunction, a term that goes beyond a simple dismissal and constrains Sandoz’s ability to launch a generic product absent compliance with the settlement’s conditions. All commercial terms remain confidential under the Settlement Agreement.
Resolution in under a year, before any claim construction or merits briefing, is consistent with ANDA litigation dynamics where the commercial cost of extended litigation often outweighs the risk of an adverse validity ruling. The stipulated injunction suggests the settlement likely includes a negotiated launch date or other entry conditions favoring AstraZeneca, though the public record is silent on specific terms. What drives the precise timeline and any royalty or market exclusivity provisions remains unknown.
Filing to Consent Judgment in 334 days
334 days — resolved before trial, consistent with ANDA settlements before claim construction
Consent judgment entered: what the stipulated injunction means for both parties
Consent judgment is more than a dismissal — it binds Sandoz by court order
A consent judgment is a court-entered order, not merely a voluntary dismissal. By stipulating to judgment and an injunction, Sandoz has accepted a binding legal constraint enforceable by contempt proceedings. This structure is common in ANDA settlements where the brand seeks certainty that any agreed generic entry date will be court-enforced, not merely contractual.
Court-enforceable injunctionAstraZeneca secures injunctive protection without litigating validity
ZS Pharma and AstraZeneca obtained a stipulated injunction against Sandoz without exposing US11738044B2 to a merits-based invalidity challenge. The patent’s validity and claim scope remain untested on the public record. This outcome preserves the patent’s commercial value and avoids the risk of an adverse finding that could have opened the door to other generic entrants.
Patent validity untestedSandoz accepts injunction — market entry terms likely negotiated, not won
Sandoz’s consent to an injunction suggests it did not secure an immediate right to launch. Any agreed generic entry date, if one exists, is embedded in the confidential Settlement Agreement and unavailable from the public docket. Sandoz avoids the cost and risk of full Hatch-Waxman litigation but foregoes a potentially precedent-setting invalidity ruling that could have benefited the broader generic industry.
Launch date terms undisclosedLOKELMA exclusivity window likely extended — other generics face a higher bar
The consent judgment does not bind third-party ANDA filers, but the absence of any public invalidity finding means US11738044B2 remains fully enforceable against subsequent challengers. Other generic companies monitoring this docket gain no litigation roadmap from the outcome. AstraZeneca’s LOKELMA franchise — a significant hyperkalemia asset — retains its IP moat for the foreseeable term of the patent.
US11738044B2 enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ZS Pharma, Inc. | Company | Pharmaceutical IP — holder of US11738044B2 covering sodium zirconium cyclosilicate (LOKELMA)Search in Eureka ↗ |
| Co-Plaintiff | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for sodium zirconium cyclosilicate oral suspensionSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gyuhyun (joanne) Bae | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Hassen Sayeed | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Yi Li | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark A. Hayden | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ZS Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Alison M. King | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Ashley Graham | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Charles B. Klein | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Jovial Wong | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict language records that the parties ‘agreed to terms and conditions representing a negotiated settlement’ and stipulated to ‘entry of judgment and an injunction.’ This phrasing confirms the outcome is a consent judgment — a court order with binding legal force — rather than a voluntary dismissal. The injunction term is commercially significant: it imposes an enforceable constraint on Sandoz beyond mere contractual obligations, and its specific scope and duration are governed by the confidential Settlement Agreement not visible on the public docket.
US11738044B2 — sodium zirconium cyclosilicate oral suspension (LOKELMA)
US11738044B2 protects sodium zirconium cyclosilicate formulations — the active ingredient in AstraZeneca’s LOKELMA, approved for the treatment of hyperkalemia (elevated blood potassium). The application (US16/415550) covers specific formulation characteristics of the oral suspension product supplied in 5 g and 10 g per-packet dosing. LOKELMA operates as a selective potassium binder in the gastrointestinal tract, and its formulation patents protect the specific physicochemical characteristics that enable its clinical profile.
From a competitive intelligence perspective, US11738044B2 represents a formulation-layer patent asset protecting a commercially significant product in the growing hyperkalemia market — an area of increasing therapeutic focus given the prevalence of chronic kidney disease and heart failure. The patent’s survival without any validity challenge in this litigation means it retains full presumptive validity. Any company developing sodium zirconium cyclosilicate-based therapies or generics must account for this patent in freedom-to-operate analyses and ANDA filing strategies.
Should you run an FTO against US11738044B2 before any LOKELMA-adjacent work?
Any R&D team or generic manufacturer working on sodium zirconium cyclosilicate oral suspension formulations — or potassium-binding products in the same therapeutic space — should treat US11738044B2 as a live enforcement risk. This case confirms AstraZeneca will litigate ANDA filings against LOKELMA promptly and has secured injunctive terms in at least one settlement. The absence of any public claim construction means the patent’s exact scope must be analyzed from first principles.
PatSnap Eureka’s FTO Search Agent can map US11738044B2’s claim boundaries against your formulation pipeline, identify related AstraZeneca and ZS Pharma application families, and surface prior art that may support a differentiation or challenge strategy. For ANDA filers and branded pharma competitors alike, an Eureka-powered FTO provides a structured risk baseline before any filing decision is made.
Run a freedom-to-operate analysis on US11738044B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases involving oral suspension formulations in Delaware
Cases involving Hatch-Waxman ANDA challenges to oral suspension pharmaceutical formulation patents in the District of Delaware, including comparable consent judgment outcomes.
What this case signals for the ANDA pharmaceutical IP landscape
LOKELMA’s consent judgment reinforces how brand pharmaceutical companies use stipulated injunctions to lock in exclusivity without courtroom risk.
Stipulated injunctions in ANDA cases signal brand-side negotiating strength
When a generic challenger consents to an injunction rather than litigating to a verdict, it typically signals that the brand holds a strong patent position or the commercial calculus favors settlement. IP teams monitoring LOKELMA competitors should note that US11738044B2 has not been invalidated and carries full enforcement weight against future ANDA filers.
No public claim construction leaves US11738044B2 scope commercially uncertain
Because the case resolved before any claim construction order, the precise boundaries of US11738044B2’s claims are untested in litigation. R&D teams designing around LOKELMA must rely on the patent’s text and prosecution history alone — without the interpretive guidance a Markman ruling would have provided. This increases FTO risk for sodium zirconium cyclosilicate formulation work.
ZS v Sandoz — key questions answered
ZS Pharma and AstraZeneca asserted US11738044B2, a patent covering sodium zirconium cyclosilicate oral suspension formulations marketed as LOKELMA, against Sandoz’s ANDA seeking to launch a generic equivalent product.
The consent judgment entered in September 2024 includes a stipulated injunction against Sandoz. The specific terms — including any agreed generic launch date — are contained in a confidential Settlement Agreement not publicly available. The injunction is court-enforceable, going beyond a contractual commitment.
No validity determination was made. The case resolved by consent judgment before any merits adjudication, leaving US11738044B2’s validity and claim scope entirely untested on the public record. The patent retains full presumptive validity.
The case was filed in the District of Delaware (Case No. 1:23-cv-01191) and assigned to Judge Jennifer L. Hall. Delaware is the predominant venue for Hatch-Waxman ANDA pharmaceutical patent litigation in the United States.
LOKELMA is AstraZeneca’s brand name for sodium zirconium cyclosilicate, an oral potassium binder approved for the treatment of hyperkalemia. Its commercial success and patent protection make it a target for generic entry via ANDA filings, triggering Hatch-Waxman litigation when patent certifications are challenged.
PatSnap Eureka searches patents and litigation data to answer instantly.